US FDA panel votes against Forest's nebivolol for heart failure
This article was originally published in Scrip
Executive Summary
The US FDA's cardiovascular and renal drugs advisory committee on January 11th unanimously recommended to the agency that it not approve Forest Laboratories' application to market its beta blocker nebivolol as a treatment for chronic heart failure (CHF).